After camptothecin and oxaliplatin treatment, OATP1B3 overexpression provides a survival advantage for wild-type p53 expressing colon cancer cell lines by altering p53-dependent survival pathways [7]. This evidence concerns the gene SLCO1B3 and malignant colon neoplasm.